Login to Your Account



Vidaza Still MDS Winner, But Market Seems Roomy

By Randall Osborne


Monday, August 29, 2005

The clock is ticking on key decisions related to a pair of drugs for myelodysplastic syndrome (MDS) - MGI Pharma Inc.'s Dacogen and Celgene Corp.'s Revlimid - and the market seems ready to widen, even as physicians continue to look fondly upon Pharmion Corp.'s injectable Vidaza (azacitidine), the compound in-licensed from Pharmacia & Upjohn Co., now part of Pfizer Inc.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription